ESMO25: Immuno-therapies and translational research in oncology, with Inge Marie Svane

At ESMO 2025 in Berlin, pharmaphorum spoke with Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, Center for Cancer Immune Therapy (CCIT), at the University of Copenhagen – about IO Biotech’s data presentation of new and updated results for IO102-IO103 (imsapepimut-etimupepimut) in the first-line treatment of metastatic (or advanced) melanoma, non-small cell lung cancer (NSCLC) and squamous cell carcinoma of head & neck (SCCHN).

Dr Svane discusses these results, the immuno-oncology field more broadly, and the most exciting conversations from the Congress as a whole.

Watch this and other videos from ESMO 2025 here.